Jefferies raises Tarsus Pharmaceuticals price target on guidance

Jefferies raised Tarsus Pharmaceuticals' price target to $105 from $88 and reiterated Buy, implying roughly 17% upside from the cited $89.69 share price. The upgrade reflects increased 2026 Xdemvy guidance, prescription trends indicating a strong Q3, and pipeline expansion through the Alkeus and iRenix acquisitions; Jefferies estimates the Alkeus rare-disease asset could generate $1 billion in peak sales. Tarsus reported Q2 net product sales of $173.9 million versus $167.33 million consensus, although its $0.43-per-share loss was wider than the expected $0.22 loss.

Analysis

TARS is transitioning from a single-product commercial story into a capital-allocation story. The equity can sustain a higher revenue multiple only if Xdemvy’s prescription growth converts into durable refill behavior and improving operating leverage; a sales beat paired with a wider loss suggests commercialization expense and gross-to-net dynamics remain more important to near-term free-cash-flow valuation than top-line momentum alone. Over the next 1-3 months, weekly prescription trends, payer access, and any further change in 2026 guidance should matter more than another sell-side target increase.

The two business-development transactions create asymmetric outcomes over a 6-18 month horizon: credible Phase III execution could broaden the addressable market and reduce dependence on Xdemvy, but pre-revenue assets also raise cash-burn, dilution, and integration risk before they contribute earnings. The market appears to be crediting sizeable peak-sales assumptions without yet observing pivotal-data quality, launch economics, or acquisition consideration; this is the principal source of downside if the next financing is equity-funded. A risk-off biotech tape would amplify that risk because TARS has materially rerated after a sharp short-term move.

Contrarian view: the immediate upside case is likely increasingly priced, while the relevant unpriced variable is whether incremental Xdemvy revenue drops through to gross profit rather than being reinvested in salesforce and pipeline expansion. Promotional references to APP and SMCI have no read-through for TARS and should not be treated as a biotech-sentiment signal. The thesis is falsified by decelerating new-to-brand scripts for two consecutive monthly periods, a reduction in product-sales guidance, or cash runway/guidance implying equity issuance before the acquired assets reach major data catalysts.

Key Decisions for Investors

• Do not chase TARS after the recent momentum move; build a long only on a pullback toward $80-84, contingent on prescription data remaining above the pace required for current guidance. Base case is a retest of $100-105 over 3-6 months; stop/reassess below $75 or after a guidance cut.
• For existing TARS exposure, retain core shares but trim 20-30% into $100-105 absent independently verified script acceleration or improved loss/expense guidance. This monetizes analyst-target upside while preserving exposure to pipeline catalysts.
• Use a defined-risk bullish structure rather than outright leverage: buy 6-9 month TARS $90/$110 call spreads only if implied volatility is not elevated following earnings. The trade requires continued commercial execution and limits exposure to acquisition-financing shocks.
• Set a financing alert: any equity raise, materially higher operating-expense outlook, or extension of cash-use guidance before pivotal readouts should trigger a reduction in TARS. The appropriate hedge for broad biotech beta is partial XBI exposure, not a short in unrelated momentum names APP or SMCI.